Cynthia X. Ma
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.
Year:
2025
Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.
Year:
2025
Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).
Year:
2025
PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).
Year:
2025
Purpose: Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. Although molecular residual disease assays show promise, their use in the neoadjuvant setting requires rapid turnaround times. Tissue-informed approaches may be challenging for patients with limited biopsy samples. The objectives were to determine the surveillance sensitivity for detecting metastatic recurrence and evaluate the ctDNA response to neoadjuvant therapy (NAT) using a tissue-free epigenomic assay. Experimental Design: Patients with stage II or III TNBC undergoing neoadjuvant docetaxel and carboplatin chemotherapy on a clinical trial (NCT02124902) followed by surgery with or without adjuvant therapy were included in this study. Blood samples were prospectively collected before, during, and after completion of NAT and after surgery at prespecified surveillance time points. Plasma samples were analyzed by Guardant Reveal. Results: A total of 119 patients with TNBC were included in the analysis. ctDNA was detected in the postsurgical setting in 8.9% (7/79) of patients, with an 83% (5/6) patient-level surveillance sensitivity for metastatic recurrence and 99.5% (197/198) sample-level specificity. Postsurgical ctDNA detection was prognostic for the shorter recurrence-free interval (HR, 37.7; P P Conclusions: In patients with early-stage TNBC, a tissue-free, epigenomic assay demonstrated high specificity and sensitivity for metastatic recurrence. ctDNA detection in the neoadjuvant setting indicated poor prognosis, highlighting its potential role across breast cancer care.
Year:
2025
Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial in regulating cell-cycle progression and cancer development. Targeting CDK4/6 has shown considerable promise in treating various cancers, including breast cancer. Despite significant therapeutic efficacy, resistance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial hurdle in clinical practice. Using a coculture system, cytokine array, and quantitative high-throughput combinatorial screening, we discovered a mechanism by which the Runt-related transcription factor (RUNX) 1–platelet-derived growth factor (PDGF)-BB axis regulates palbociclib resistance in breast cancer cells. Specifically, RUNX1 functioned as a transcription factor to drive expression of PDGFB , leading to resistance to palbociclib by enhancing the Akt pathway and suppressing senescence. Furthermore, in resistant cells, RUNX1 was O-GlcNAcylated at serine 252 by O-GlcNAc transferase, resulting in the stabilization of RUNX1 by preventing ubiquitin-mediated degradation. Inhibition of the RUNX1–PDGF-BB axis by specific inhibitors overcame palbociclib resistance both in vitro and in vivo . Notably, the RUNX1–PDGF-BB axis was upregulated in resistant patient-derived xenograft lines and in patients with breast cancer following treatment with CDK4/6i. These findings not only unveil O-GlcNAcylation–mediated activation of a RUNX1–PDGF-BB pathway as a driver of palbociclib resistance but also provide clinical evidence supporting the repurposing of FDA-approved PDGFR inhibitors as a therapeutic strategy to treat patients with CDK4/6i-resistant breast cancer. Significance: RUNX1-PDGF-BB signaling drives resistance to CDK4/6 inhibition in breast cancer, providing the foundation to develop approaches to target the RUNX1-PDGF-BB axis to overcome CDK4/6 inhibitor resistance in breast cancer patients.
Year:
2025
Purpose: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described. Experimental Design: We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single-nucleotide variants, copy-number variants, and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways. Results: Patients with HER2-low had higher rates of PIK3CA mutations [relative risk ratio (RRR), 1.57; P = 0.024] compared with HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR, 12.43; P = 0.002 for amplification; RRR, 3.22; P = 0.047 for mutations, in the hormone receptor–positive cohort), fewer ERS1 mutations (RRR, 0.458; P = 0.029), and fewer ER pathway alterations (RRR, 0.321; P P Conclusions: We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between patients with HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.
Year:
2025
Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA's predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Minimal residual disease (MRD) detection via ctDNA to detect clinical recurrence after curative therapy is a rapidly advancing field. In this review, we discuss the existing and emerging data regarding ctDNA utility in both MBC and EBC settings.
Year:
2024
Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-α-positive (ER + ) breast cancer, however drug resistance is common. In this study, proteogenomic analyses of patient-derived xenografts (PDXs) from patients with 22 ER + breast cancer demonstrated that protein kinase, membrane-associated tyrosine/threonine one (PKMYT1), a WEE1 homolog, is estradiol (E2) regulated in E2-dependent PDXs and constitutively expressed when growth is E2-independent. In clinical samples, high PKMYT1 mRNA levels associated with resistance to both ET and CDK4/6 inhibition. The PKMYT1 inhibitor lunresertib (RP-6306) with gemcitabine selectively and synergistically reduced the viability of ET and palbociclib-resistant ER + breast cancer cells without functional p53. In vitro the combination increased DNA damage and apoptosis. In palbociclib-resistant, TP53 mutant PDX-derived organoids and PDXs, RP-6306 with low-dose gemcitabine induced greater tumor volume reduction compared to treatment with either single agent. Our study demonstrates the clinical potential of RP-6306 in combination with gemcitabine for ET and CDK4/6 inhibitor resistant TP53 mutant ER + breast cancer.
Year:
2024
Introduction: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates (ADC). While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described. Materials and Methods: We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 TM from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single nucleotide variants (SNVs), copy number variants (CNVs), and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways. Results: Patients with HER2-low had higher rates of PIK3CA mutations (RRR 1.57, P=0.024) compared to HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR 12.43, P=0.002 for amplification; RRR 3.22, P=0.047 for mutations, in the HR+ cohort), fewer ERS1 mutations (RRR 0.458, P=0.029) and fewer ER pathway alterations (RRR 0.321, P PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (48)
Aparna Mitra
Staff scientist
Baylor College of Medicine
Carolina Reduzzi
Assistant Professor
Weill Cornell Medicine
Todd A. Fehniger
Professor
Washington University School of Medicine
Andrew A. Davis
Washington University in St. Louis
Cornelius von Morze
-
Gerburg Wulf
Harvard University
Sherri Davies
Senior Scientist
Washington University in St. Louis
Rachel Schiff
Professor
Baylor College of Medicine
Ron Bose
Washington University School of Medicine
Priyanka Sharma
Associate Professor
University of Kansas Medical Center
PAVANKUMAR TANDRA
Assistant professor with a special interest in Breast Oncology
University of Nebraska Medical Center
Angela DeMichele
University of Pennsylvania
Meenakshi Anurag
Assistant Professor (Tenure track)
Baylor College of Medicine
Foluso O. Ademuyiwa
-
Zhuqing Li
Assistant Research Professor
George Washington University
Mateusz Opyrchal
Associate Professor
Indiana University School of Medicine
Yara G Abdou
University of North Carolina at Chapel Hill
Junfeng Ma
Georgetown University Medical Center
Jairam Krishnamurthy
Huntsman Cancer Institute
susan hilsenbeck
Professor
Baylor College of Medicine
Edward Seto
The George Washington University School of Medicine and Health SCiences
Matthew J. Ellis
Director
Baylor College of Medicine
Kooresh Shoghi
Professor
Washington University in St. Louis
Harold Burstein
Professor
Dana-Farber Cancer Institute
Matthew Goetz
Professor of Oncology and Pharmacology
Mayo Clinic
Sonya Reid
Vanderbilt University Medical Center
Jason M. Held
Washington University School of Medicine
Amir Behdad
-
Shunqiang Li
Associate Professor
Washington University in St. Louis
CARMINE DE ANGELIS
Associate Professor
University of Naples Federico II
Charles Foulds
Assistant Professor
Baylor College of Medicine
Rama Suresh
Associate Professor
Washington University in St. Louis
Matthew Hall
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850
Robert Mashl
Washington University in St. Louis
Suzanne Fuqua
Professor
Baylor College of Medicine
Wenge Zhu
Professor
The George Washington University School of Medicine and Health SCiences
Rubina Qamar
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Shuyan Zhou
George Washington University
Kathy Miller
Indiana University Bloomington
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Chunyan Hou
Georgetown University
Aditya Bardia
UCLA Health
Erica Mayer
Dana-Farber Cancer Institute
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
YANJUN GAO
George Washington University
Lindsay L. Peterson
Washington University School of Medicine
jingqin luo
Associate Professor
Washington University in Saint Louis School of Medicine
Reshma Mahtani
Chief of Breast Medical Oncology
Sylvester Comprehensive Cancer Center, University of Miami
Make your next move.
Prepare your application
Review drafts before you send them.